Golubovskaya Vita, Berahovich Robert, Xu Shirley, Harto Hizkia, Wu Lijun
Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806. United States.
Anticancer Agents Med Chem. 2017;17(10):1344-1350. doi: 10.2174/1871520617666170110151900.
Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new, highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization. The report summarizes major pharmaceutical companies developing these novel therapies and provides challenges and perspectives for future therapeutic developments.
嵌合抗原受体T细胞（CAR-T）疗法和T细胞受体（TCR）-T细胞疗法等细胞免疫疗法是相对较新的、极具前景的癌症治疗方法。在CAR-T细胞疗法中，患者的T细胞经过改造，以表达靶向肿瘤相关细胞表面抗原的嵌合抗原受体。在TCR-T细胞疗法中，患者的T细胞经过改造，以表达靶向细胞内抗原的受体。本报告将总结2016年9月13日至16日在波士顿举行的近期CAR-TCR峰会上的演讲内容。这些演讲由该领域的领军人物发表，许多演讲分为三个部分：发现与基因T细胞工程；转化与临床开发；以及制造、供应链与商业化。该报告总结了开发这些新型疗法的主要制药公司，并为未来的治疗发展提供了挑战和展望。
